Exelixis Puts '184 Back in Spotlight With "Dramatic" Prostate Cancer Results
This article was originally published in The Pink Sheet Daily
In interim Phase II data, the unpartnered drug reverses bone lesions in metastatic prostate cancer patients.
You may also be interested in...
As cabozantinib wins FDA approval for the rare medullary thyroid cancer, Exelixis stresses its broader development program in other tumor types, notably prostate cancer. The company is likely to submit prostate cancer data to compendia, which if successful could enable reimbursement for the off-label use.
Exelixis says one pain study may do it for approval, despite losing an SPA with FDA and the agency’s preference for an overall survival endpoint.
The results from the event-driven pivotal trial of Exelixis Inc.’s cabozantinib in medullary thyroid cancer will be delayed by three more months, but there is a good chance for a positive outcome.